Search

Your search keyword '"Bréant, Valentine"' showing total 22 results
Start Over Author "Bréant, Valentine"
22 results on '"Bréant, Valentine"'

1. Pharmacie clinique et pédiatrie : une carte mentale

Author

Lecoeur, Anne, Leleux, Agathe, Berthe-Aucejo, Aurore, Viard, Caroline, de Cursay, Claire Lambert, Navas, Dominique, Choquet, Elise, Jandot, Elise, Capelle, Héloïse, Maffre, Irène, Goyer, Isabelle, Hugueny, Jeanne, Agar, Julien, Beuzit, Karine, Rasamison, Riana, Masseron, Sandrine, Chanoine, Sébastien, Le Moulec, Stéphanie, Bréant, Valentine, and Prot-Labarthe, Sonia

Published
2024
Full Text
View/download PDF

8. Connaissez-vous le Guide d’aide à la prescription, la dispensation et l’administration des médicaments en pédiatrie de l’Omédit Normandie ?

Author

Agar, Julien, Beuzit, Karine, Berthe-Aucejo, Aurore, Bourdon, Olivier, Breant, Valentine, Capelle, Héloïse, Chanoine, Sébastien, Choquet, Elise, Goyer, Isabelle, Hugueny, Jeanne, Jandot, Elise, Lambert De Cursay, Claire, Lecoeur, Anne, Leleux, Agathe, Le Moulec, Stéphanie, Maffre, Irène, Masseron, Sandrine, Navas, Dominique, Prot-Labarthe, Sonia, Rasamison, Riana, Viard, Caroline, Cherel, Albane, Bouglé, Céline, and Delbende, Eulalie

Published
2024
Full Text
View/download PDF

10. Impact of COVID-19 pandemic on antifungal consumption: a multicenter retrospective analysis.

Author

Bienvenu, Anne-Lise, Bestion, Audrey, Pradat, Pierre, Richard, Jean-Christophe, Argaud, Laurent, Guichon, Céline, Roux, Sandrine, Piriou, Vincent, Paillet, Carole, Leboucher, Gilles, the Antifungal study group, Ader, Florence, Aubrun, Frédéric, Besson, Charlotte, Bréant, Valentine, Doudet, Charlotte, Ducastelle-Leprêtre, Sophie, Dupont, Damien, Guillemin, Marie-Delphine, and Leray, Véronique

Abstract

Background: In the context of COVID-19 pandemic, antifungal overuse may have occurred in our hospitals as it has been previously reported for antibacterials. Methods: To investigate the impact of COVID-19 on antifungal consumption, a multicenter retrospective study including four medical sites and 14 intensive care units (ICU) was performed. Antifungal consumption and incidences of invasive fungal diseases before and during COVID-19 pandemic, for non-COVID-19 patients and COVID-19 patients, were described. Results: An increase in voriconazole consumption was observed in 2020 compared with 2019 for both the whole hospital and the ICU (+ 40.3% and + 63.7%, respectively), whereas the incidence of invasive aspergillosis significantly increased in slightly lower proportions in the ICU (+ 46%). Caspofungin consumption also increased in 2020 compared to 2019 for both the whole hospital and the ICU (+ 34.9% and + 17.0%, respectively) with an increased incidence of invasive candidiasis in the whole hospital and the ICU but in lower proportions (+ 20.0% and + 10.9%, respectively). Conclusions: We observed an increased consumption of antifungals including voriconazole and caspofungin in our hospital during the COVID-19 pandemic and explained in part by an increased incidence of invasive fungal diseases in COVID-19 patients. These results are of utmost importance as it raises concern about the urgent need for appropriate antifungal stewardship activities to control antifungal consumption. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

11. Efficacy and Safety of a 0.1% Tacrolimus Nasal Ointment as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial

Author

Dupuis-Girod, Sophie, Fargeton, Anne-Emmanuelle, Grobost, Vincent, Rivière, Sophie, Beaudoin, Marjolaine, Decullier, Evelyne, Bernard, Lorraine, Bréant, Valentine, Colombet, Bettina, Philouze, Pierre, Bailly, Sabine, Faure, Frédéric, Hermann, Ruben, Hospices Civils de Lyon (HCL), BioSanté (UMR BioSanté), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Grenoble Alpes (UGA), CHU Clermont-Ferrand, CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Famille BMP dans l'angiogenèse et la lymphangiogenèse (BAL ), Biologie du Cancer et de l'Infection (BCI ), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Grenoble Alpes (UGA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), and Bailly, Sabine

Subjects
nasal ointment, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, epistaxis, genetic disease, lcsh:R, lcsh:Medicine, hereditary hemorrhagic telangiectasia, rare disease, nosebleeds, tacrolimus, Article, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system
Abstract

Hereditary hemorrhagic telangiectasia is a rare but ubiquitous genetic disease. Epistaxis is the most frequent and life-threatening manifestation and tacrolimus, an immunosuppressive agent, appears to be an interesting new treatment option because of its anti-angiogenic properties. Our objective was to evaluate, six weeks after the end of the treatment, the efficacy on the duration of nosebleeds of tacrolimus nasal ointment, administered for six weeks to patients with hereditary hemorrhagic telangiectasia complicated by nosebleeds, and we performed a prospective, multicenter, randomized, placebo-controlled, double-blinded, ratio 1:1 phase II study. Patients were recruited from three French Hereditary Hemorrhagic Telangiectasia (HHT) centers between May 2017 and August 2018, with a six-week follow-up, and we included people aged over 18 years, diagnosed with hereditary hemorrhagic telangiectasia and epistaxis (total duration &gt, 30 min/6 weeks prior to inclusion). Tacrolimus ointment 0.1% was self-administered by the patients twice daily. About 0.1 g of product was to be administered in each nostril with a cotton swab. A total of 50 patients was randomized and treated. Mean epistaxis duration before and after treatment in the tacrolimus group were 324.64 and 249.14 min, respectively, and in the placebo group 224.69 and 188.14 min, respectively. Epistaxis duration improved in both groups, with no significant difference in our main objective comparing epistaxis before and after treatment (p = 0.77), however, there was a significant difference in evolution when comparing epistaxis before and during treatment (p = 0.04). Toxicity was low and no severe adverse events were reported. In conclusion, tacrolimus nasal ointment, administered for six weeks, did not improve epistaxis in HHT patients after the end of the treatment. However, the good tolerance, associated with a significant improvement in epistaxis duration during treatment, encouraged us to perform a phase 3 trial on a larger patient population with a main outcome of epistaxis duration during treatment and a longer treatment time.

Published
2020
Full Text
View/download PDF

12. Auteurs de la 5e édition

Author

Renaudin Pierre, Batisse Marie, Bernard-Arnoux Florian, Lehmann Audrey, Goehringer François, Nivoix Yasmine, Ratsimbazafy Voa, Limat Samuel, Bacle Astrid, Burgos Leon Cécile, Mary Aurélien, Csajka Chantal, Baudrant Magalie, Prot-Labarthe Sonia, Charmillon Alexandre, Bardet Jean-Didier, Trout Hervé, Grellet Jean, Bréant Valentine, Janoly-Dumenil Audrey, Roustit Matthieu, Bernard Lise, Buyse Marion, Gueneau Pauline, Pulcini Céline, Levêque Dominique, Hallit Souheil, Sallerin Brigitte, Bertrand Marie-Anne, Terrier-Lenglet Aurélie, Navas Dominique, Nerich Virginie, Bertin Philippe, Venisse Sandrine, Kaiser Jean-Daniel, Sebahoun Pascale, Venisse Nicolas, Pagès Arnaud, Mercié Martial, Calop Nathalie, Manuelli Marine, Asseray Nathalie, Dine Thierry, Gibaud Stéphane, Brion Françoise, Chautant Fiona, Mondoloni Pauline, Cazin Jean-Louis, Dupuis Antoine, Huon Jean-François, Bochaton Thomas, Sautou Valérie, Calop Jean, Sabatier Brigitte, Diehl Jean-Luc, Breilh Dominique, Korb-Savoldelli Virginie, Chanoine Sébastien, Clairet Anne-Laure, Fernandez Christine, Jouanny Pierre, Meyer Florence, Mornex Jean-François, Mongaret Kossmann Céline, Vergne-Salle Pascale, Laborde Charlotte, Gérard Blandine, Capelle Aude, Guignard Bertrand, Salameh Pascale, Kodjikian Laurent, Honoré Stéphane, Mille Frédéric, Calvet Pauline, Aulagner Gilles, Tron Camille, Fagnoni Philippe, Moulin Philippe, Binson Guillaume, Boulieu Roselyne, Bugnon Olivier, Pin Isabelle, Marie Nicolas, Bonhomme-Faivre Laurence, Derimay François, Pison Christophe, Montani David, Fardellone Patrice, Leroy Joël, Castet-Nicolas Audrey, Larger Magali, Rouault Anne, Korb Diane, Dode Xavier, Naudet Florian, Dousset Virginie, Sebbag Laurent, Ragot Stéphanie, Peyrière Hélène, Grare Marion, Fournel Alexandra, Hindlet Patrick, Bonvin Aurélie, Potin Sophie, Reix Philippe, Aparicio Thomas, Herbrecht Raoul, Duval Raphaël, Ubeaud-Séquier Geneviève, Boursier Amélie, Le Turnier Paul, Lebargy François, Hajj Aline, Bedouch Pierrick, Armoiry Xavier, Bourdon Olivier, Vukusic Sandra, Boulin Mathieu, Malet Louise, Puisset Florent, Cestac Philippe, Rouch Laure, Barrail-Tran Aurélie, Caron Philippe, Béjot Yannick, Tauveron Igor, Brazier Michel, Lemaitre Florian, Demoré Béatrice, Bonnabry Pascal, Ottomani Hélène, Ploteau Stéphane, Monnot Tess, Potie Laudine, Jost Jeremy, Beney Johnny, Chapuis Claire, Le Moal Gwenaël, Sacre Hala, Hansel-Esteller Sylvie, Bourcier Elsa, Quillet Pauline, Chekroud Hacène, Allenet Benoît, and Ragon Alain

Published
2018

14. Pharmacie clinique et pédiatrie : une carte mentale

Author

Prot-Labarthe, Sonia, Lecoeur, Anne, Leleux, Agathe, Berthe-Aucejo, Aurore, Viard, Caroline, de Cursay, Claire Lambert, Navas, Dominique, Choquet, Elise, Jandot, Elise, Capelle, Héloïse, Maffre, Irène, Goyer, Isabelle, Hugueny, Jeanne, Agar, Julien, Beuzit, Karine, Rasamison, Riana, Masseron, Sandrine, Chanoine, Sébastien, Le Moulec, Stéphanie, and Bréant, Valentine

Published
2024
Full Text
View/download PDF

15. Effect of Bevacizumab Nasal Spray on Epistaxis Duration in Hereditary Hemorrhagic Telangectasia

Author

Dupuis-Girod, Sophie, primary, Ambrun, Alexis, additional, Decullier, Evelyne, additional, Fargeton, Anne-Emmanuelle, additional, Roux, Adeline, additional, Bréant, Valentine, additional, Colombet, Bettina, additional, Rivière, Sophie, additional, Cartier, César, additional, Lacombe, Pascal, additional, Chinet, Thierry, additional, Blivet, Sandra, additional, Blondel, Jean-Hugues, additional, Gilbert-Dussardier, Brigitte, additional, Dufour, Xavier, additional, Michel, Justin, additional, Harle, Jean-Robert, additional, Dessi, Patrick, additional, and Faure, Frédéric, additional

Published
2016
Full Text
View/download PDF

17. The effect of methylphenidate on neurofibromatosis type 1: a randomised, doubleblind, placebo-controlled, crossover trial.

Author

Lion-François, Laurence, Gueyffier, François, Mercier, Catherine, Gérard, Daniel, Herbillon, Vania, Kemlin, Isabelle, Rodriguez, Diana, Ginhoux, Tiphanie, Peyric, Emeline, Coutinho, Virginie, Bréant, Valentine, Portes, Vincent des, Pinson, Stéphane, Combemale, Patrick, and Kassaï, Behrouz

Subjects
METHYLPHENIDATE, NEUROFIBROMATOSIS, POLYCYSTIC kidney disease, ATTENTION-deficit hyperactivity disorder, LEARNING disabilities
Abstract

Background Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder with an estimated prevalence of about 1/3000, independent of ethnicity, race, or gender. Attention Deficit Hyperactivity like Disorder (ADHD)-like characteristics are often reported in patients with NF1. We hypothesised that learning disabilities in NF1 children were related to ADHD symptoms. Treatment with methylphenidate (MPD) has improved learning disabilities in ADHD by acting on neurotransmitters. Our objective was to evaluate its efficacy on ADHDlike symptoms in neurofibromatosis type 1 children (7-12 years). Methods This was a randomised, double blind, placebo controlled, and crossover trial comparing 0.5 to 0.8 mg/kg/d of MPD as it is indicated for ADHD to placebo in NF1 children with ADHD-like symptoms. Children aged 7 to 12 years were eligible when their IQ was between 80 and 120. The total follow-up was 9 weeks including 4 weeks for each period and 1 week wash out. Fifty subjects (25 for each period) were required for testing the primary study hypothesis. The main outcome was an improvement in scores on the simplified Conners' Parent Rating Scale. Results Thirty-nine patients were included between April 2004 and December 2010. Twenty participants received MPD and 19 placebo during the first period. They all completed the trial. MPD decreased the simplified Conners by 3.9 points (±1.1, p = 0. 0003). Conclusions This is the first randomised controlled trial showing the short-term benefit of MPD on simplified Conners scores in NF1 children. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

19. LES AUTEURS

Author

ALLENET, Benoît, APARICIO, Thomas, ARMOIRY, Xavier, AULAGNER, Gilles, BALLEREAU, Françoise, BARDET, Jean-Didier, BARRAIL-TRAN, Aurélie, BATISSE, Marie, BAUDRANT, Magalie, BEDOUCH, Pierrick, BENEY, Johnny, BERTAND, Marie-Anne, BEVILACQUA, Sibylle, BONHOMME-FAIVRE, Laurence, BONNABRY, Pascal, BONVIN, Aurélie, BOULIEU, Roselyne, BOULIN, Mathieu, BOURDON, Olivier, BOUTOILLE, David, BOYER-GRAND, Anne, BRAZIER, Michel, BRÉANT, Valentine, BREILH, Dominique, BREUKER, Cyril, BRION, Françoise, BRUNET, Philippe, BUGNON, Olivier, BURGOS LEON, Cécile, BUYSE, Marion, CABARET, Blandine, CALOP, Jean, CALOP, Nathalie, CARON, Philippe, CASTET-NICOLAS, Audrey, CERTAIN, Agnès, CESTAC, Philippe, CHANOINE, Sébastien, CHAPUIS, Claire, CHEKROUD, Hacène, CHOPINEAU, Jean, CHOUCHANE, Nabil, CSAJKA, Chantal, DALLEUR, Olivia, DAVRINCHE, Catherine, DEJEAN, Catherine, DEMORÉ, Béatrice, DIEHL, Jean-Luc, DI MARTINO, Cyrille, DINE, Thierry, DODE, Xavier, DOUSSET, Virginie, DUPUIS, Antoine, DUVAL, Raphaël, FAGNONI, Philippe, FARDELLONE, Patrice, FARINOTTI, Robert, FERNANDEZ, Christine, FERREIRA, Ema, FOUCHER, Nadine, GIBAUD, Stéphane, GIRARD-TOURNILHAC, Isabelle, GOURDIER, Bertrand, GRARE, Marion, GRELLET, Jean, GUICHARD, Sylvie, GUIGNARD, Bertrand, HANSEL-ESTELLER, Sylvie, HERBRECHT, Raoul, HINDLET, Patrick, HUET, Estelle, IVANES, Fabrice, JAAFARI, Nematollah, KAISER, Jean-Daniel, KARNIB AMAL, Al-Hajje, KALTENBACH, Matthieu, KODJIKIAN, Laurent, LACOUR, Valérie, LARGER, Magali, LEBARGY, François, LEHMANN, Audrey, LEMAITRE, Florian, LE MOAL, Gwenaël, LEROY, Joël, LEVÊQUE, Dominique, LIMAT, Samuel, LOPES, Patrice, LUYCKX, Michel, MAILHOT, Claude, MALLET, Louise, MARQUET, Aurélie, MARY, Aurélien, METZ, Damien, MILLE, Frédéric, MONTANI, David, MORIN, Caroline, MORNEX, Jean-François, NAVAS, Dominique, NERICH, Virginie, NIVOIX, Yasmine, OLLIVIER, Florence, OUAHCHI, Zeineb, PAYSANT, Mélanie, PEYRIÈRE, Hélène, PHARAND, Chantal, PIN, Isabelle, PISON, Christophe, POTIE, Laudine, PROT-LABARTHE, Sonia, PUISSET, Florent, RAGON, Alain, REIX, Philippe, REY, Evelyne, RICHARD, Denis, ROUAULT, Anne, ROUSTIT, Matthieu, SABATIER, Brigitte, SALAMEH, Pascale, SALLERIN, Brigitte, SAMAR, Rachidi, SANAA, Awada, SAUTOU-MIRANDA, Valérie, SAUX, Marie-Claude, SEBBAG, Laurent, SENON, Jean-Louis, SHOUSHA, Sherif, SIBELLAS, Franck, SPINEWINE, Anne, TAUVERON, Igor, TROUT, Hervé, TULKENS, Paul M., UBEAUD-SÉQUIER, Geneviève, VACHER-COPONAT, Henri, VENISSE, Nicolas, VENISSE, Sandrine, VUKUSIC, Sandra, WILLIAMSON, David, WORONOFF-LEMSI, Marie-Christine, and ZAKIA HARZALLAH, Inès

Published
2012
Full Text
View/download PDF

20. The effect of methylphenidate on neurofibromatosis type 1: a randomised, double-blind, placebo-controlled, crossover trial.

Author

Lion-François, Laurence, Gueyffier, François, Mercier, Catherine, Gérard, Daniel, Herbillon, Vania, Kemlin, Isabelle, Rodriguez, Diana, Ginhoux, Tiphanie, Peyric, Emeline, Coutinho, Virginie, Bréant, Valentine, des Portes, Vincent, Pinson, Stéphane, Combemale, Patrick, Kassaï, Behrouz, and Réseau NF1 Rhône Alpes Auvergne-France

Abstract

Background: Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder with an estimated prevalence of about 1/3000, independent of ethnicity, race, or gender. Attention Deficit Hyperactivity like Disorder (ADHD)-like characteristics are often reported in patients with NF1. We hypothesised that learning disabilities in NF1 children were related to ADHD symptoms. Treatment with methylphenidate (MPD) has improved learning disabilities in ADHD by acting on neurotransmitters. Our objective was to evaluate its efficacy on ADHD-like symptoms in neurofibromatosis type 1 children (7-12 years).Methods: This was a randomised, double blind, placebo controlled, and crossover trial comparing 0.5 to 0.8 mg/kg/d of MPD as it is indicated for ADHD to placebo in NF1 children with ADHD-like symptoms. Children aged 7 to 12 years were eligible when their IQ was between 80 and 120. The total follow-up was 9 weeks including 4 weeks for each period and 1 week wash out. Fifty subjects (25 for each period) were required for testing the primary study hypothesis. The main outcome was an improvement in scores on the simplified Conners' Parent Rating Scale.Results: Thirty-nine patients were included between April 2004 and December 2010. Twenty participants received MPD and 19 placebo during the first period. They all completed the trial. MPD decreased the simplified Conners by 3.9 points (±1.1, p = 0. 0003).Conclusions: This is the first randomised controlled trial showing the short-term benefit of MPD on simplified Conners scores in NF1 children.Trial Registration: ClinicalTrials.gov NCT00169611. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

22. Integrated clinical pharmacy activities into the pediatric kidney graft pathway

Author

Martin J, Jandot É, Bréant V, Sellier-Leclerc AL, Mouchoux C, Lattard C, Bacchetta J, Larger M, Dode X, and Hoegy D

Subjects
Humans, Child, Kidney, Kidney Transplantation methods, Pharmacy
Abstract

The pediatric renal graft pathway is at risk of care discontinuation, even though therapeutic adherence is essential. The objective is to evaluate the integration of clinical pharmacy activities into this care pathway. This feasibility study is divided into three stages: structuring, implementing and evaluation. In pre-transplant, immediate and remote post-transplant, interviews were proposed as well as the pharmaceutical analysis of medication prescriptions. In 8 months duration, 32 patients were included. All patients included in pre-transplant and immediate post-transplant benefited from the activities. At M0, all the prescriptions analyzed resulted in at least one problem detected. Half of the transplanted patients benefited from M1 maintenance, one patient from M3 maintenance and no M6 follow-up could be carried out. This work concludes with the good feasibility and integration of clinical pharmacy activities within the care pathway.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results